A phase III trial to investigate the immunogenicity of the VLA2001 vaccine, developed by Valneva, has recently started at multiple sites across the UK.

Dr Iain Page is the local PI overseeing the trial here at the Edinburgh site, where nearly 200 participants have been enrolled to take part in the study. They have been randomised to receive either the new VLA2001 vaccine, or AstraZeneca’s Vaxzervia vaccine which is already approved and in wide-scale deployment across the globe.

The participants will be followed up over the coming months to gather safety and immunogenicity data that will help inform the overall safety and effectiveness of this new vaccine.

This is incredibly exciting as we need new vaccines to expand capacity in order to help address the global need for vaccination against COVID-19.

Click here to find out more.